Search

Your search keyword '"Allergan PLC -- Product development"' showing total 18 results
Start Over Descriptor "Allergan PLC -- Product development" Topic medical research
18 results on '"Allergan PLC -- Product development"'

1. Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, GSK PLC -- Product development, Nestlé S.A. -- Product development, Medical research, Medicine, Experimental, Patient compliance, Atopic dermatitis, Roflumilast -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 7, 2025-: Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch [...]

Published
2025

2. Allergan, Editas Medicine begin patient dosing in phase 1/2 trial of CRISPR Medicine AGN-151587 (EDIT-101) to treat LCA1

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Blindness -- Care and treatment, Genetic disorders -- Care and treatment, Genomics, Genetic research, Genes, Health, Pharmaceuticals and cosmetics industries, Oregon Health & Science University
Abstract

Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 [...]

Published
2020

3. Allergan, Molecular Partners present data from phase 3 studies of Abicipar in patients with neovascular wet AMD at AAO m

Subjects
Allergan PLC -- Product development, Clinical trials, Macular degeneration, Ranibizumab, Medical research, Pharmaceutical industry -- Product development, Ophthalmology, Pharmaceuticals and cosmetics industries, American Academy of Ophthalmology
Abstract

Allergan plc, a leading global pharmaceutical company, and Molecular Partners, a clinical-stage biopharmaceutical company, announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with [...]

Published
2019

4. US FDA accepts Allergan's NDA for ubrogepant for acute treatment of migraine

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Medical research, Migraine -- Drug therapy, Prescriptions (Drugs) -- Product development, Legal fees, Clinical trials, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults. The [...]

Published
2019

5. Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight

Subjects
Allergan PLC -- Product development, Bayer AG -- Product development, Medical research, Medicine, Experimental, Trospium -- Product development, Clinical trials, Darifenacin -- Product development, Pharmaceutical industry -- Product development, Business, international, Law
Abstract

(GlobeNewswire) - Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight Overactive Bladder therapies with different mechanisms of action are currently being studied with excellent [...]

Published
2021

6. New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

Subjects
Allergan PLC -- Product development, Roche Holding AG -- Product development, Medical research, Medicine, Experimental, Biotechnology industry -- Product development, Clinical trials, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Venclexta (Medication) -- Product development
Abstract

- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are [...]

Published
2020

7. Allergan announces new data from CENTAUR phase 2b study supports continued development of CVC in ongoing phase 3 AURORA trial

Subjects
Allergan PLC -- Product development, Clinical trials, Liver diseases -- Care and treatment, Medical research, Pharmaceutical industry -- Product development, Liver, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced top-line results from new data for the CENTAUR phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis [...]

Published
2017

8. Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Clinical trials, Medical research, Contraceptives -- Product development, Levonorgestrel, Medical societies, Obstetricians, Women's health, Contraceptive drug implants, Health, Physicians, General interest, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

SAN FRANCISCO and DUBLIN: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc [...]

Published
2019

9. Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S

Subjects
Allergan PLC -- Product development, Women -- Health aspects, Medical research, Medicine, Experimental, Pregnancy, Levonorgestrel -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN, May 6, 2019 /PRNewswire/ -- Medicines360, a nonprofit [...]

Published
2019

10. Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Drug therapy, Constipation -- Drug therapy, Medical research, Pharmaceutical industry -- Product development, Drug approval, Business, Business, international, Linzess (Medication)
Abstract

- Trial designed to more comprehensively evaluate the effect of linaclotide 290 mcg on bothersome abdominal symptoms, including bloating, discomfort and pain, associated with IBS-C - CAMBRIDGE, Mass. -- Ironwood [...]

Published
2018

11. Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

SAN FRANCISCO: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), [...]

Published
2018

12. Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Subjects
Allergan PLC -- Product development, Women -- Health aspects, Medical research, Medicine, Experimental, Levonorgestrel -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting SAN FRANCISCO and DUBLIN, April 30, 2018 /PRNewswire/ -- [...]

Published
2018

13. Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

Dublin: Allergan plc (AGN) has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE II (UBR-MD-02), the second of [...]

Published
2018

14. Allergan submits NDA with the US FDA for ubrogepant to treat migraine

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Medical research, Prescriptions (Drugs) -- Product development, Migraine -- Care and treatment, Clinical trials, Legal fees, Chemistry
Abstract

M2 PHARMA-March 12, 2019-Allergan submits NDA with the US FDA for ubrogepant to treat migraine (C)2019 M2 COMMUNICATIONS Pharmaceutical company Allergan plc (NYSE:AGN) said on Monday that it has successfully [...]

Published
2019

15. Allergan submits NDA with the US FDA for ubrogepant to treat migraine

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Medical research, Prescriptions (Drugs) -- Product development, Migraine -- Care and treatment, Clinical trials, Legal fees, Business
Abstract

M2 EQUITYBITES-March 12, 2019-Allergan submits NDA with the US FDA for ubrogepant to treat migraine (C)2019 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Allergan plc (NYSE:AGN) said on Monday that it has [...]

Published
2019

16. Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX(r) (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)

Subjects
Allergan PLC -- Product development, Major depressive disorder -- Care and treatment, Medical research, Botulinum toxins -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Allergan plc.: Allergan plc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced topline data from a Phase II study with Major [...]

Published
2017

17. Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation IBS-C

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Drug therapy, Constipation -- Drug therapy, Medical research, Pharmaceutical industry -- Product development, Drug approval, Biotechnology industry, Biological sciences, Business, Linzess (Medication)
Abstract

2018 JUL 30 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, announced the initiation of a [...]

Published
2018

18. Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Health, American College of Obstetricians and Gynecologists
Abstract

2018 MAY 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results